Expert consensus on antiviral therapy of COVID-19
- VernacularTitle:新型冠状病毒感染者抗病毒治疗专家共识
- Author:
Fujie ZHANG
1
;
Zhuo WANG
;
Quanhong WANG
;
Qing MAO
;
Jinsong BAI
;
Hanhui YE
;
Jia TIAN
;
Tianxin XIANG
;
Jihong AN
;
Zujiang YU
;
Wenjie YANG
;
Xingxiang YANG
;
Xiaoju ZHANG
;
Jie ZHANG
;
Lina ZHANG
;
Xingwang LI
;
Jiabin LI
;
Manxiang LI
;
Zhiwei LI
;
Hourong ZHOU
;
Yi SHI
;
Xiaoling XU
;
Xiaoping TANG
;
Hong TANG
;
Xixin YAN
;
Wenxiang HUANG
;
Chaolin HUANG
;
Liang DONG
;
Baosong XIE
;
Jiandong JIANG
;
Bin XIONG
;
Xuemei WEI
;
Jifang SHENG
;
Ronghua JIN
Author Information
- Keywords: Coronavirus; COVID-19; Antiviral therapy; Early stage; Expert consensus
- From: Chinese Journal of Clinical Infectious Diseases 2023;16(1):10-20
- CountryChina
- Language:Chinese
- Abstract: COVID-19 is caused by a novel coronavirus-severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), which has being spreading around the world, posing a serious threat to human health and lives. Neutralizing antibodies and small molecule inhibitors for virus replication cycle are the main antiviral treatment for novel coronavirus recommended in China. To further promote the rational use of antiviral therapy in clinical practice, the National Center for Infectious Diseases (Beijing Ditan Hospital Capital Medical University and the First Affiliated Hospital, Zhejiang University School of Medicine) invited experts in fields of infectious diseases, respiratory and intensive care to develop an Expert Consensus on Antiviral Therapy of COVID-19 based on the Diagnosis and Treatment Guideline for COVID-19 ( trial version 10) and experiences in the diagnosis and treatment of COVID-19 in China. The consensus is concise, practical and highly operable, hopefully it would improve the understanding of antiviral therapy for clinicians and provide suggestions for standardized medication in treatment of COVID-19.
